Hindustan Unilever Ltd (HUL) is funding a research project to understand the immune response to SARS-CoV-2 among vaccinated people and vaccine efficacy among Indians.
The national-level research is being enabled by the office of the principal scientific adviser to the government of India’s programme that will work on collaborations between industry and academia.
HUL will also support additional analytical and data analyses through its R&D scientists to the consortium partners, it said.
- Go-Digit’s Second Day of IPO: Latest Updates and RHP Details
- Digital Competition Bill Can Hinder With Tech Startup’s Investment Plans
- Government is Planning to Changing Base Year for Key Economic Indices to FY23
- Matel Raises $4 Million Through Series A Funding
- US Increases Taxes on Batteries and Chips from China; Might Impact India
“This is a first-of-its-kind national-level multi-centre study on long-term protection and immunogenicity of vaccines, in combination with an understanding of nutritional and ‘skin immunity’ status in the Indian population,” the company said in a statement on Tuesday.
Stock Covered in the news